| ID | 1310 |
| Name of the vaccine | DD 687 or DF 098 |
| Microbe | Bacteria |
| Disease name | Tetanus (Lock Jaw) |
| Name of bacteria | Clostridium tetani |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 2 to 68 months |
| Description of the vaccine | DTaP-IPV vaccine and Hib vaccine. |
| Name of the manufacturer | Sanofi Pasteur, a Sanofi Company |
| Name of the manufacturing country | Japan |
| Year of manufacture | 2016 |
| Clinical Phase status | Clinical - Phase 3 |
| Bacterial strain | Gram-positive bacteria. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Three doses of 0.5 mL, each given 3 to 8 weeks apart. |
| Mechanism of action | NA |
| Route of administration | Subcutaneous |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For pertussis, diphtheria, poliomyelitis and bacterial meningitis. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination (3 doses) |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT02274285 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|